Immuno oncology

Immunotherapy Drug Improves Overall Survival in Patients With Cervical Cancer
According to a phase II study, an immunotherapy targeting HPV-infected cells led to a one-year survival rate among patients with recurrent metastatic cervical cancer.
Advancing Immunotherapy Impact in Bladder Cancer
BY Gina Columbus
In an interview with CURE, Arlene O. Siefker-Radtke, M.D., discusses immune treatment and the immune landscape for the treatment of patients with urothelial cancers.
Using Evolving Knowledge to Manage Cancer's Side Effects
BY Len Lichtenfeld, M.D.
Should patients avoid immunotherapy because of the side effects that have been reported? Dr. Lichtenfeld shares his thoughts.
Expert Weighs in on Promising New Options for Frontline Kidney Cancer
BY Angelica Welch
David McDermott, M.D. discusses new advances made to treat kidney cancer. 
Kidney Cancer Trial Recommended to Halt
BY Silas Inman
An independent data monitoring committee recommended that the phase 3 ADAPT trial exploring rocapuldencel-T (AGS-003) for the frontline treatment of metastatic renal cell carcinoma (mRCC) be stopped, but Argos Therapeutics explained that they will keep the trial open. 
Combination May Move to the Frontline for Kidney Cancer
A randomized trial showed that the combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) has some promise for the frontline treatment of some patients with RCC.
Keytruda Benefits Rare Melanoma Subtype in Three Trials
BY Lisa Miller
Three recent trials showed that Keytruda had a durable response for patients with a rare subtype of melanoma.
Immunotherapy Data is Encouraging in Kidney Cancer
BY Danielle Bucco
Elizabeth Plimack, M.D., discusses an update on the CheckMate-025 trial, comparing Opdivo to Afinitor in patients with metastatic renal cell carcinoma.
Expert Discusses Keytruda's Future in Lung Cancer
BY Allie Strickler
Roy Herbst, M.D., Ph.D., spoke with CURE about the future of Keytruda, and immunotherapy in general, to treat lung cancer.
Managing Immunotherapy Side Effects in Melanoma: Quick Intervention Is Key
BY Allie Casey
Immunotherapy agents have their own set of side effects, and managing them quickly and efficiently is key.
Special Feature
Share Your Art
Talk about this article with other patients, caregivers, and advocates in the Immuno-oncology CURE discussion group.
Search Cancer Drugs & Terms